Cambridge Consultants has supported SCHOTT forma vitrum ag in developing a new syringe system - InJentle™ - designed to address the requirements of highly sensitive drugs as well as improving the application, making injections less painful for patients.
Cambridge Consultants followed a risk-based approach to devise, design and develop a robust and reliable solution. Considering all aspects of the required functionality, we created a design that met the functional and commercial requirements of this safety critical device. It was also designed to meet the stringent requirements of the pharmaceutical industry, with particular attention being paid to assembly, sterilisation and material selection.
InJentle's patented design, employing a ‘pinch seal’ closure, ensures that the drug is not in contact with the metal needle or the adhesive of the syringe during storage, preventing sensitive drugs from interacting with these potential contaminants. This also has the advantage of creating similar stability test requirements as vials. The needle shield has also been designed with robust tamper-evident closure.
“We are delighted with the result of this partnership with Cambridge Consultants, whose experience of developing novel injection technology has been invaluable in getting this product to the manufacture stage so effectively." commented Carmen Heiter Product Manager, Syringes, at SCHOTT
Related Press Releases
UK: +44 (0)1223 420024
US: +1 617 532 4700
SG: +65 6827 5675